MannKind Corporation to Present at The 31st Annual J.P. Morgan Healthcare Conference
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing
and commercializing treatments for diabetes and cancer, announced today
that it will present at The 31st Annual J.P. Morgan Healthcare
Conference on Thursday, January 10, 2013 at 8:00 AM (PST) at St. Francis
Hotel in San Francisco, California.
Interested parties can access a link to the live webcast of the
presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery,
development and commercialization of therapeutic products for patients
with diseases such as diabetes and cancer. Its lead product candidate,
AFREZZA®, is in late stage clinical investigation for the treatment of
adults with type 1 or type 2 diabetes for the control of hyperglycemia.
MannKind maintains a website at www.mannkindcorp.com
to which MannKind regularly posts copies of its press releases as well
as additional information about MannKind. Interested persons can
subscribe on the MannKind website to e-mail alerts that are sent
automatically when MannKind issues press releases, files its reports
with the Securities and Exchange Commission or posts certain other
information to the website.
